Table 3.
Platelet reactivity and rate of HPR according to metabolic phenotype
| CYP2C19 | CYP3A5 | ABCB1 3435C > T | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Extensive metabolizer (n = 48) | Intermediate metabolizer (n = 54) | Poor metabolizer (n = 25) | *1/*1 (n = 10) | *1/*3 (n = 43) | *3/*3 (n = 74) | CC (n = 52) | CT (n = 62) | TT (n = 13) | |
| light transmittance aggregometry | |||||||||
| 5 µm ADP-aggmax (%) | |||||||||
| Mean ± SD | 24.6 ± 13.3 | 28.7 ± 12.2 | 32.3 ± 15.7 | 27.0 ± 14.9 | 28.4 ± 13.6 | 27.7 ± 13.5 | 27.4 ± 13.8 | 27.9 ± 13.7 | 29.7 ± 12.5 |
| 95% CI | 20.8, 28.5 | 25.4, 32.0 | 25.8, 38.7 | 16.3, 37.6 | 24.2, 32.6 | 24.5, 30.8 | 23.5, 31.2 | 24.4, 31.4 | 22.1, 37.3 |
| P value (anova) | 0.062 | 0.934 | 0.855 | ||||||
| P value (Jonckheere-Terpstra) | 0.016 | 0.678 | 0.538 | ||||||
| 5 µM ADP-Agglate (%) | |||||||||
| Mean ± SD | 12.1 ± 12.2 | 16.4 ± 11.1 | 21.0 ± 14.0 | 14.9 ± 10.2 | 15.9 ± 13.8 | 15.6 ± 12.1 | 15.4 ± 13.2 | 16.2 ± 12.6 | 14.1 ± 9.2 |
| 95% CI | 8.6, 15.7 | 13.3, 19.4 | 15.2, 26.7 | 7.6, 22.2 | 11.7, 20.2 | 12.8, 18.4 | 11.8, 19.1 | 13.0, 19.4 | 8.5, 19.7 |
| P value (anova) | 0.021 | 0.972 | 0.846 | ||||||
| P value (Jonckheere-Terpstra) | 0.002 | 0.933 | 0.859 | ||||||
| 20 µm ADP-Aggmax (%) | |||||||||
| Mean ± SD | 34.2 ± 16.7 | 41.7 ± 14.2 | 44.9 ± 17.0 | 41.4 ± 19.6 | 40.2 ± 16.5 | 38.8 ± 15.7 | 39.3 ± 16.5 | 38.7 ± 16.3 | 44.1 ± 14.6 |
| 95% CI | 29.3, 39.0 | 37.8, 45.6 | 37.9, 51.9 | 27.3, 55.4 | 35.1, 45.3 | 35.2, 42.5 | 34.7, 43.9 | 34.5, 42.8 | 35.3, 52.9 |
| P value (anova) | 0.007 | 0.845 | 0.551 | ||||||
| P value (Jonckheere-Terpstra) | 0.003 | 0.601 | 0.596 | ||||||
| 20 µm ADP-Agglate (%) | |||||||||
| Mean ± SD | 18.5 ± 17.4 | 27.1 ± 16.8 | 32.9 ± 18.1 | 28.8 ± 21.4 | 24.3 ± 19.7 | 24.8 ± 16.7 | 25.0 ± 18.6 | 24.1 ± 17.6 | 28.7 ± 18.4 |
| 95% CI | 13.4, 23.5 | 22.5, 31.6 | 25.4, 40.4 | 13.5, 44.1 | 18.2, 30.4 | 21.0, 28.7 | 19.8, 30.2 | 19.7, 28.6 | 17.6, 39.8 |
| P value (anova) | 0.002 | 0.775 | 0.713 | ||||||
| P value (Jonckheere-Terpstra) | <0.001 | 0.990 | 0.696 | ||||||
| VerifyNow P2Y12 assay | |||||||||
| P2Y12 reaction units | |||||||||
| Mean ± SD | 125 ± 76 | 188 ± 75 | 226 ± 88 | 164 ± 75 | 173 ± 92 | 172 ± 86 | 172 ± 88 | 169 ± 86 | 186 ± 91 |
| 95% CI | 103, 147 | 168, 209 | 190, 262 | 111, 218 | 145, 201 | 152, 192 | 147, 196 | 147, 191 | 131, 241 |
| P value (anova) | <0.001 | 0.958 | 0.824 | ||||||
| P value (Jonckheere-Terpstra) | <0.001 | 0.975 | 0.880 | ||||||
| HPR (5 µM ADP-induced Aggmax >46%) | |||||||||
| n (%) | 3 (6.3) | 4 (7.4) | 5 (20.0) | 1 (10.0) | 5 (11.6) | 6 (8.1) | 7 (13.5) | 4 (6.5) | 1 (7.7) |
| P value | 0.099 | 0.620 | 0.279 | ||||||
CYP, cytochrome P450; ABCB1, ATP-binding cassette sub-family B member 1; ADP, adenosine diphosphate; Aggmax, maximal platelet aggregation; Agglate, late platelet aggregation at 5 min; HPR, high on-treatment platelet reactivity.